Pregled bibliografske jedinice broj: 303222
Rosiglitazone Therapy of Diabetes Mellitus in Acromegaly Causes Significant Reduction of Growth Hormone and Insulin-like Growth Hormone I Secretion
Rosiglitazone Therapy of Diabetes Mellitus in Acromegaly Causes Significant Reduction of Growth Hormone and Insulin-like Growth Hormone I Secretion // Endocrinologist, 17 (2007), 4; 204-205 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 303222 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Rosiglitazone Therapy of Diabetes Mellitus in Acromegaly Causes Significant Reduction of Growth Hormone and Insulin-like Growth Hormone I Secretion
Autori
Gradišer, Marina ; Matovinović, Martina ; Vrkljan, Milan
Izvornik
Endocrinologist (1051-2144) 17
(2007), 4;
204-205
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
rosiglitazone; acromegaly; diabetes mellitus
Sažetak
We presented woman with acromegaly and diabetes mellitus. Transsphenoidal resection of the macroadenoma confirmed histologically a GH-secreting pituitary adenoma. Since the removal of the tumor was incomplete, medical therapy was instituted. A PPAR-gama agonist was administered to treat residual diabetes.Suprisengly, there was improvement in acromegaly features with decrease levels of GH and IGF-I.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
